Rentabilitas dodolan miturut bathi resik: VBI Vaccines Inc. (VBIV)

vbivaccines.com (VBIV) - logo korporat

Actual net profit margin reflects business efficiency dynamics, where 0.00 captures the current state of the parameter. Supply stability to developing countries relies on strict temperature control of medications. VBI Vaccines (VBIV) develops VLP-based drugs against Ebola and hepatitis B for global healthcare systems. Patent protection of innovative developments in oncology and virology ensures the company's resilience during sales optimization.

VBIV: Margin resik vbivaccines.com 04.07.2022 - 17.08.2024

Rincian analitis lan laporan data perusahaan vbivaccines.com (VBIV)

- rega saham lan prakiraan rega para ahli:
Analisis dhasar perusahaan:VBI Vaccines - VBIV
Barang unggulan VBI Vaccines Inc.

Investors are cautiously assessing the potential of VBI Vaccines Inc. (VBIV) amid high sector uncertainty. This metric captures the portion of profit from every dollar of revenue after deducting all operating and tax expenses. Analyzing the history of net profit margin reveals the efficiency of cost management. This is critical for biotech, as logistical disruptions in raw material supplies from Asia instantaneously compress margins. The asset is categorized as a high-risk speculative security.